SYNGENE stock news on Anadi Algo News

Wednesday, April 29, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
Stock Landing|2 matching stories

SYNGENE Share Price, Latest News & Sentiment

Latest AI-analyzed news for SYNGENE, along with saved share-price context, sentiment, quarterly filing summary, and related names in one page.

Stock Coverage Hub

SYNGENE News Today

Emerging stock coverage

The CRDMO sector in India is experiencing significant growth, driven by outsourcing trends from global pharmaceutical companies. Companies with strong client relationships and consistent growth are highly valued.

Coverage
2
recent stories
Sources
2
distinct publishers
Bias Split
1 bullish / 0 bearish
1 neutral stories
Window
3d
recent coverage span
Saved Quote Snapshot

Syngene International Limited

Last Updated
29 Apr 2026
Price
Rs 440.5
+0.58%
52W Range
Rs 380 - Rs 728.6
exchange snapshot
PE / VWAP
PE 50.12
VWAP Rs 439.41
Trend Read
bullish
Bullish stack · EMA 5 > 9 > 21 > 50
Business Context
Industry: Healthcare Research Analytics & Technology
Sector Trail: NIFTY MIDCAP150 QUALITY 50
Listing Date: 2015-08-11
Market Structure
F&O Eligible: No
Indices: NIFTY MIDCAP150 QUALITY 50, NIFTY500 SHARIAH, NIFTY 500
Snapshot Source: mcp+nse
Quarterly Read

Quarter ended 31 Dec 2024

Consolidated results
What This Quarter Says

This is the latest financial report for Syngene. The company made ₹943.7 crore in sales and ₹131.1 crore in profit. This information is on record for your review.

Revenue
Rs 943.7 cr
up 7.6% vs previous filing
Profit
Rs 131.1 cr
up 6.5% vs previous filing
EPS / Finance Cost
EPS 3.27
Finance cost Rs 12.4 cr
Filing Context
Filed 24 Jan 2025, 12:10 am
Figures are taken from the saved exchange filing, not from a live request.
Quick Reader Notes
  • Revenue this quarter: Rs 943.7 cr, up 7.6% vs previous filing.
  • Profit this quarter: Rs 131.1 cr, up 6.5% vs previous filing.
  • EPS gives a quick sense of per-share earnings: 3.27.
How To Read This

Treat this block as a saved quarter snapshot. First see whether revenue and profit are improving, then read the latest news below to judge whether recent headlines support that trend or work against it.

SYNGENE FAQ

Why is SYNGENE in the news right now?

SYNGENE has appeared across 2 recent stories from 2 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.

Is SYNGENE coverage bullish or bearish right now?

SYNGENE coverage is currently leaning bullish, with 1 bullish, 0 bearish, and 1 neutral analyzed stories in the recent window.

Which themes are moving with SYNGENE?

Recent SYNGENE coverage is clustering around fmcg and pharma. Related names showing up alongside SYNGENE include MUTHOOTFIN, TATACONSUM.

How should I use this SYNGENE news page?

Use this page as a coverage hub for SYNGENE: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.

Workflow View

Use SYNGENE coverage to build a cleaner watchlist.

A stock page is most useful when it helps you slow down, compare headlines, and separate one-off noise from a repeatable setup.

This is here if you want to go deeper, not as a push.Explore Anadi
Investors should monitor the CRDMO space for companies demonstrating strong growth and client acquisition, as this indicates robust business fundamentals.|Quick check: SYNGENE bearish bias (oversold), SUNPHARMA neutral (-1.4% 1d).